hypericin has been researched along with Cancer of Pituitary in 3 studies
Excerpt | Relevance | Reference |
---|---|---|
"When hypericin treated cells were not exposed to light growth inhibition was insignificant." | 5.31 | Light-induced photoactivation of hypericin inhibits cellular growth in pituitary adenoma cell line AtT20/D16v-F2 (hypericin inhibits cellular growth of AtT20/D16v-F2). ( Cerman, J; Mareková, M; Vávrová, J; Vokurková, D, 2001) |
"Two established pituitary adenoma cell lines, AtT-20 and GH4C1, were treated with hypericin in tissue culture for defined periods following passage." | 5.29 | Inhibition of cellular growth and induction of apoptosis in pituitary adenoma cell lines by the protein kinase C inhibitor hypericin: potential therapeutic application. ( Chen, ZH; Couldwell, WT; Gopalakrishna, R; Hamilton, HB; Hinton, DR; Law, RE; Su, YZ; Weiss, MH, 1996) |
"Hypericin was administered in four doses (1 mg/kg) at 28-h intervals prior to light exposure, wherein those rats treated with light were exposed to a light source four hours after the last hypericin dose." | 1.35 | Hypericin-mediated photodynamic therapy of pituitary tumors: preclinical study in a GH4C1 rat tumor model. ( Chin, SS; Cole, CD; Couldwell, WT; Liu, JK; Schmidt, MH; Sheng, X; Weiss, MH, 2008) |
"When hypericin treated cells were not exposed to light growth inhibition was insignificant." | 1.31 | Light-induced photoactivation of hypericin inhibits cellular growth in pituitary adenoma cell line AtT20/D16v-F2 (hypericin inhibits cellular growth of AtT20/D16v-F2). ( Cerman, J; Mareková, M; Vávrová, J; Vokurková, D, 2001) |
"Two established pituitary adenoma cell lines, AtT-20 and GH4C1, were treated with hypericin in tissue culture for defined periods following passage." | 1.29 | Inhibition of cellular growth and induction of apoptosis in pituitary adenoma cell lines by the protein kinase C inhibitor hypericin: potential therapeutic application. ( Chen, ZH; Couldwell, WT; Gopalakrishna, R; Hamilton, HB; Hinton, DR; Law, RE; Su, YZ; Weiss, MH, 1996) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cole, CD | 1 |
Liu, JK | 1 |
Sheng, X | 1 |
Chin, SS | 1 |
Schmidt, MH | 1 |
Weiss, MH | 2 |
Couldwell, WT | 2 |
Hamilton, HB | 1 |
Hinton, DR | 1 |
Law, RE | 1 |
Gopalakrishna, R | 1 |
Su, YZ | 1 |
Chen, ZH | 1 |
Mareková, M | 1 |
Vávrová, J | 1 |
Vokurková, D | 1 |
Cerman, J | 1 |
3 other studies available for hypericin and Cancer of Pituitary
Article | Year |
---|---|
Hypericin-mediated photodynamic therapy of pituitary tumors: preclinical study in a GH4C1 rat tumor model.
Topics: Animals; Anthracenes; Apoptosis; In Situ Nick-End Labeling; Perylene; Photochemotherapy; Pituitary N | 2008 |
Inhibition of cellular growth and induction of apoptosis in pituitary adenoma cell lines by the protein kinase C inhibitor hypericin: potential therapeutic application.
Topics: Adenoma; Animals; Anthracenes; Apoptosis; Cell Division; Perylene; Pituitary Neoplasms; Protein Kina | 1996 |
Light-induced photoactivation of hypericin inhibits cellular growth in pituitary adenoma cell line AtT20/D16v-F2 (hypericin inhibits cellular growth of AtT20/D16v-F2).
Topics: Adenoma; Animals; Anthracenes; Apoptosis; Cell Cycle; Cell Division; DNA, Neoplasm; Dose-Response Re | 2001 |